When it comes to product development, the management of third-party intellectual property (IP) to ensure freedom to operate is of paramount importance. Drug development is no different. Imagine ...
Roche Holding AG was barred by an appeals court on Friday from selling the anemia drug Mircera in the United States, after a judge found that the company infringes Amgen Inc.’s patents. The U.S. Court ...
BOSTON, Sept 5 (Reuters) - Amgen Inc and Roche Holding AG laid out opening arguments on Wednesday in a trial that will determine whether Roche can sell its anemia drug Mircera in the United States to ...
Amgen Inc. said late Tuesday that a U.S. district court issued a final injunction that bars Swiss drug maker Roche Group from selling its anemia drug Mircera in the United States until 2014. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results